Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

The relationship between experience and mental workload in anaesthetic practice: an observational study.

Byrne AJ, Murphy A, McIntyre O, Tweed N.

Anaesthesia. 2013 Dec;68(12):1266-72. doi: 10.1111/anae.12455. Epub 2013 Oct 28.

2.

Monitoring of MMPs activity in vivo, non-invasively, using solubility switchable MRI contrast agent.

Jastrzebska B, Lebel R, McIntyre OJ, Paquette B, Neugebauer W, Escher E, Lepage M.

Adv Exp Med Biol. 2009;611:453-4. No abstract available.

PMID:
19400263
3.

Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule.

Kesari A, Pirra LN, Bremadesam L, McIntyre O, Gordon E, Dubrovsky AL, Viswanathan V, Hoffman EP.

Hum Mutat. 2008 May;29(5):728-37. doi: 10.1002/humu.20722.

PMID:
18348289
4.

A concise history of the cancer and leukemia group B.

Schilsky RL, McIntyre OR, Holland JF, Frei E 3rd.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3553s-5s. Review.

5.

Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy.

Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP.

Neurology. 2005 Sep 27;65(6):826-34. Epub 2005 Aug 10.

PMID:
16093456
6.

Differential synaptic processing separates stationary from transient inputs to the auditory cortex.

Atzori M, Lei S, Evans DI, Kanold PO, Phillips-Tansey E, McIntyre O, McBain CJ.

Nat Neurosci. 2001 Dec;4(12):1230-7.

PMID:
11694887
7.

Interaction between delta-9-tetrahydrocannabinol and indomethacin.

Green K, Kearse EC, McIntyre OL.

Ophthalmic Res. 2001 Jul-Aug;33(4):217-20.

PMID:
11464074
8.

Influence of dehydroepiandrosterone on rabbit intraocular pressure.

Kearse EC, McIntyre OL, Johnson MH, Phillips CI, Lathe R, Adams W, Green K.

Ophthalmic Res. 2001 Jan-Feb;33(1):42-7.

PMID:
11114604
9.

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E 3rd, McIntyre OR, Schilsky RL.

J Clin Oncol. 1999 May;17(5):1397-406.

PMID:
10334524
10.

Pilot survey of opinions on data falsification in clinical trials.

McIntyre OR, Kornblith AB, Coburn J.

Cancer Invest. 1996;14(4):392-5. No abstract available.

PMID:
8689435
11.

Placebo-controlled randomized study of hydrazine sulfate in lung cancer.

Kosty MP, Herndon JE 2nd, Green MR, McIntyre OR.

J Clin Oncol. 1995 Jun;13(6):1529-30. No abstract available.

PMID:
7751903
12.

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd.

N Engl J Med. 1994 Oct 6;331(14):896-903.

13.

Acute leukemia and residential proximity to potential sources of environmental pollutants.

Shore DL, Sandler DP, Davey FR, McIntyre OR, Bloomfield CD.

Arch Environ Health. 1993 Nov-Dec;48(6):414-20.

PMID:
8250593
14.

A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.

Weiss RB, Vogelzang NJ, Peterson BA, Panasci LC, Carpenter JT, Gavigan M, Sartell K, Frei E 3rd, McIntyre OR.

JAMA. 1993 Jul 28;270(4):459-64.

PMID:
8320783
15.

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.

Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, Bernhardt B, Duggan D, Faragher D, Schiffer C.

J Clin Oncol. 1993 Jan;11(1):155-60.

PMID:
8418228
16.

Age related changes in adults with acute leukemia.

Schiffer CA, McIntyre OR.

Adv Exp Med Biol. 1993;330:215-29. Review. No abstract available.

PMID:
8368134
17.

ras oncogene activation and occupational exposures in acute myeloid leukemia.

Taylor JA, Sandler DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, McIntyre OR, Liu E.

J Natl Cancer Inst. 1992 Nov 4;84(21):1626-32.

PMID:
1433344
18.

Mood and clinical status in patients with multiple myeloma.

Silberfarb PM, Anderson KM, Rundle AC, Holland JC, Cooper MR, McIntyre OR.

J Clin Oncol. 1991 Dec;9(12):2219-24.

PMID:
1960562
19.

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.

Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C.

Blood. 1991 Nov 15;78(10):2520-6.

20.

Community screening for cervical cancer in New Hampshire.

Dietrich AJ, Carney-Gersten P, Holmes DW, McIntyre OR, Reed S, Clauson B, Zaso K.

J Fam Pract. 1989 Sep;29(3):319, 321, 323. No abstract available.

PMID:
2769198
21.

Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.

Dillman RO, Mick R, McIntyre OR.

J Clin Oncol. 1989 Apr;7(4):433-8.

PMID:
2784491
22.

Phase II trial of amsacrine in patients with multiple myeloma.

Greipp PR, Coleman M, Anderson K, McIntyre OR.

Med Pediatr Oncol. 1989;17(1):76-8.

PMID:
2913481
23.

NCI Cancer Education Grant Program: vague promises of nourishment for budding creativity.

McIntyre OR.

J Cancer Educ. 1989;4(2):83-4. No abstract available.

PMID:
2641330
24.
25.

Melphalan and prednisone plus total bone marrow irradiation as initial treatment for multiple myeloma.

McIntyre OR, Tefft M, Propert K, Wolf DJ, Coleman M, Leone L, Cooper MR, Eaton W, Zimmer B.

Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):1007-12.

PMID:
3182309
26.

Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.

Cornwell GG 3rd, Pajak TF, Kochwa S, McIntyre OR, Glowienka LP, Brunner K, Rafla S, Coleman M, Cooper MR, Henderson E, et al.

J Clin Oncol. 1988 Sep;6(9):1481-90.

PMID:
3047338
27.

Distribution of the 124-kd antigen defined by monoclonal antibody AML-1-99 on normal and leukemic myeloid cells.

Howell AL, Miller R, Keefe KA, McIntyre OR, Stockner M, Sullivan R, Hibbert SR, Noelle RJ, Ball ED.

Exp Hematol. 1988 Mar;16(3):176-83.

PMID:
3422192
28.

Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.

Capizzi RL, Davis R, Powell B, Cuttner J, Ellison RR, Cooper MR, Dillman R, Major WB, Dupre E, McIntyre OR.

J Clin Oncol. 1988 Mar;6(3):499-508.

PMID:
3162515
29.

Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.

Vredenburgh JJ, McIntyre OR, Cornwell GG 3rd, Ball ED, Cornell CJ, Mills LE, O'Donnell JF.

Med Pediatr Oncol. 1988;16(3):187-9.

PMID:
3380061
30.

Asbestos as a health hazard: a course for college students.

McIntyre OR.

J Cancer Educ. 1988;3(1):9-10. No abstract available.

PMID:
3275222
31.

Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B.

Rai KR, Cuttner J, Holland JF, Davis R, Mayer R, McIntyre OR, Preisler H, Yates J.

Haematol Blood Transfus. 1987;30:31-4. No abstract available.

PMID:
3305203
32.

Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia.

Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, McIntyre OR, Bloomfield CD.

Blood. 1986 Dec;68(6):1232-41.

33.

Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results.

Sporn JR, McIntyre OR.

Semin Oncol. 1986 Sep;13(3):318-25. Review. No abstract available.

PMID:
3532330
34.

Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.

Cooper MR, McIntyre OR, Propert KJ, Kochwa S, Anderson K, Coleman M, Kyle RA, Prager D, Rafla S, Zimmer B.

J Clin Oncol. 1986 Sep;4(9):1331-9.

PMID:
3528403
35.

Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study.

Mayer RJ, Schiffer CA, Peterson BA, Silver RT, Cornwell GG, McIntyre OR, Rai KR, Budman DR, Ellison RR, Maguire M, et al.

Semin Oncol. 1985 Jun;12(2 Suppl 3):84-90. No abstract available.

PMID:
4012343
36.

Diaziquone for resistant multiple myeloma. Cancer and Leukemia Group B.

Vinciguerra V, Anderson K, McIntyre OR.

Cancer Treat Rep. 1985 Mar;69(3):331-2. No abstract available.

PMID:
3884154
37.

Response rate and survival in myeloma patients receiving prednisone alone.

McIntyre OR, Pajak TF, Kyle RA, Cornwell GG 3rd, Leone L.

Med Pediatr Oncol. 1985;13(5):239-43.

PMID:
4033539
38.

Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols.

Brubaker LH, Wasserman LR, Goldberg JD, Pisciotta AV, McIntyre OR, Kaplan ME, Modan B, Flannery J, Harp R.

Am J Hematol. 1984 May;16(4):367-73.

PMID:
6720682
39.

Chlorozotocin: phase II evaluation in patients with myeloma.

Cornell CJ Jr, Pajak TF, McIntyre OR.

Cancer Treat Rep. 1984 Apr;68(4):685-6. No abstract available.

PMID:
6231990
40.

Combined modality approach in the management of locally advanced head and neck cancer.

Coughlin CT, Grace M, O'Donnell JF, LeMarbre PJ, Morain WD, Geurkink NA, McIntyre OR.

Cancer Treat Rep. 1984 Apr;68(4):591-7.

PMID:
6201269
41.

Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia.

Ball ED, Bernier GM, Cornwell GG 3rd, McIntyre OR, O'Donnell JF, Fanger MW.

Blood. 1983 Dec;62(6):1203-10.

42.

Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.

Cornwell GG 3rd, Pajak TF, Kochwa S, McIntyre OR, Glowienka LP, Brunner K, Rafla S, Silver RT, Cooper MR, Henderson E, Kyle RA, Haurani FI, Cuttner J.

Cancer. 1982 Nov 1;50(9):1669-75.

PMID:
7116299
43.

Whole bone marrow irradiation for the treatment of multiple myeloma.

Coleman M, Saletan S, Wolf D, Nisce L, Wasser J, McIntyre OR, Tulloh M.

Cancer. 1982 Apr 1;49(7):1328-33.

PMID:
7037161
44.

Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.

Cornwell GG 3rd, Pajak TF, McIntyre OR, Kochwa S, Dosik H.

Cancer Treat Rep. 1982 Mar;66(3):475-81.

PMID:
7060036
45.

Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.

Kyle RA, Pajak TF, Henderson ES, Nawabi IU, Brunner K, Henry PH, McIntyre OR, Holland JF.

Cancer Treat Rep. 1982 Mar;66(3):451-6.

PMID:
7060034
46.

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK.

Blood. 1981 Dec;58(6):1203-12. No abstract available.

47.

Influence of therapy on causes of death in polycythemia vera.

Wasserman LR, Balcerzak SP, Berk PD, Berlin NI, Donovan PB, Dresch C, Ellis JT, Goldberg JD, Landaw SA, Laszlo J, McIntyre OR, Najean Y, Pisciotta AV, Silverstein MN, Tartaglia AP, Tatarsky I, Weinfeld A.

Trans Assoc Am Physicians. 1981;94:30-8. No abstract available.

PMID:
7344226
48.

Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.

Kyle RA, Gailani S, Seligman BR, Blom J, McIntyre OR, Pajak TF, Holland JF.

Cancer Treat Rep. 1979 Aug;63(8):1265-9.

PMID:
476704
49.

Current concepts in cancer. Multiple myeloma.

McIntyre OR.

N Engl J Med. 1979 Jul 26;301(4):193-6. Review. No abstract available.

PMID:
377077
50.

Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.

Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J.

Blood. 1979 Jul;54(1):13-22.

Supplemental Content

Loading ...
Support Center